Patients with Advanced or Metastasised Non-Small-Cell Lung Cancer with
PD-1 inhibitor
PD-L1 inhibitor
Viscum album L. extracts
lung cancer
non-small-cell lung cancer
real-world data study
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Apr 2024
22 Apr 2024
Historique:
received:
04
03
2024
revised:
09
04
2024
accepted:
17
04
2024
medline:
27
4
2024
pubmed:
27
4
2024
entrez:
27
4
2024
Statut:
epublish
Résumé
Immunotherapy with PD-1/PD-L1 inhibitors has significantly improved the survival rates of patients with metastatic non-small-cell lung cancer (NSCLC). Results of a real-world data study investigating add-on VA (
Identifiants
pubmed: 38672690
pii: cancers16081609
doi: 10.3390/cancers16081609
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Abnoba (Germany)
ID : n.a.
Organisme : Helixor Heilmittel (Germany)
ID : n.a.